Trial · NCT07908745
Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC
NCT07908745, Phase 3, Not yet recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC. Trials, record NCT07908745. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908745
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC
- NCT number
- NCT07908745
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 276 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Reduced-Dose Thoracic Radiotherapy, Standard-Dose Thoracic Radiotherapy
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1-Year Progression-Free Survival (PFS) rate | 1 year after randomization | Proportion of participants who are alive and free of disease progression at 1 year after randomization. Disease progression is assessed by investigators according to RECIST 1.1 using CT/MRI/PET-CT, with imaging performed every 2-3 months after randomization. The primary analysis will be performed in the intention-to-treat (ITT) population. The study will test noninferiority of reduced-dose thoracic radiotherapy versus standard-dose thoracic radiotherapy, with a noninferiority margin of 15% absolute difference in the 1-year PFS rate. Noninferiority will be concluded if the lower limit of the one-sided 97.5% confidence interval for the difference (reduced-dose minus standard-dose) is greater than -15%. |
| Secondary | 2-year Progression-Free Survival (PFS) | 2 years after randomization (or until disease progression, death, or end of follow-up, whichever occurs first). | Proportion of participants who are alive and free of disease progression at 2 years after randomization. Disease progression is assessed according to RECIST 1.1. The 2-year PFS rate will be estimated using the Kaplan-Meier method in the intention-to-treat (ITT) population. |
| Secondary | Overall Survival | From randomization until death or end of study follow-up | Time from randomization to death from any cause. Participants alive at the last follow-up will be censored. Estimated using the Kaplan-Meier method in the ITT population. |
| Secondary | Objective Response Rate (ORR) | From randomization through the treatment and follow-up period (assessed every 2-3 months; approximately 12-18 months per participant). | Proportion of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. Assessed in the ITT population(assessed every 2-3 months; approximately 12-18 months per participant). |
| Secondary | Incidence of Grade ≥3 Adverse Events (AEs) | From randomization through radiotherapy and ICI maintenance, and during follow-up (approximately 18 months per participant). | Proportion of participants experiencing at least one grade ≥3 adverse event, graded according to NCI-CTCAE v5.0 (early AEs) and RTOG late toxicity criteria (late AEs). Assessed in the safety set. |
| Secondary | Treatment Discontinuation Rate | From randomization through completion of radiotherapy and ICI maintenance (approximately 12 months per participant). | Proportion of participants who discontinue radiotherapy or ICI maintenance early for any reason. Assessed in the ITT population. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908745
GET https://conductscience.org/api/trials/v1/NCT07908745/registered